GERN

Geron Corporation · NASDAQ

Sector Health Technology
Industry Biotechnology
Website geron.com
Employees(FY) 107
ISIN US3741631036

Performance

-10.97%

-7.92%

-26.37%

-22.27%

+65.4%

YTD

+61.57%

Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Advanced Technical Analysis

Technical Analysis of GERN 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance, while the Oscillators Score at 40 suggests a neutral stance. Overall, the combined scores point to a lack of bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GERN

Stock Rank

Recent News & Updates

2024-12-19 16:30
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-12-19 03:30
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-12-18 13:19
Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72%(Simply Wall St.)
2024-12-14 06:40
Geron announces positive CHMP opinion for Rytelo(TipRanks)
2024-12-13 06:36
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS(Business Wire)
2024-12-12 17:36
Geron Announces Positive CHMP Opinion for RYTELO (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS(Businesswire)
2024-12-10 09:00
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies(Business Wire)
2024-12-10 09:00
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis(Business Wire)
2024-12-09 20:00
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies(Businesswire)
2024-11-27 09:00
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference(Business Wire)
2024-11-26 20:00
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference(Businesswire)
2024-11-21 16:30
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)
2024-11-21 13:02
High Growth Tech Stocks to Watch in November 2024(Simply Wall St.)
2024-11-21 03:30
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Businesswire)
2024-11-11 16:30
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development(Business Wire)
2024-11-11 09:00
Geron to Participate in the Stifel 2024 Healthcare Conference(Business Wire)
2024-11-11 03:30
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development(Businesswire)
2024-11-10 20:00
Geron to Participate in the Stifel 2024 Healthcare Conference(Businesswire)
2024-11-10 08:56
Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results(Simply Wall St.)
2024-11-09 07:15
Geron Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
2024-11-08 07:29
Geron Secures $250M Funding and Strong Q3 Sales(TipRanks)
2024-11-07 07:10
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million(GlobeNewswire)
2024-11-07 07:01
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors(Business Wire)
2024-11-07 07:00
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Business Wire)
2024-11-06 18:10
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million(Globenewswire)
2024-11-06 18:01
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors(Businesswire)
2024-11-06 18:00
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Businesswire)
2024-11-05 09:00
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies(Business Wire)
2024-11-04 20:00
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO (imetelstat) in Myeloid Hematologic Malignancies(Businesswire)
2024-10-17 16:30
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Business Wire)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.